SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CIANCETTA, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.251
EU - Europa 2.932
AS - Asia 2.315
SA - Sud America 493
Continente sconosciuto - Info sul continente non disponibili 173
AF - Africa 66
OC - Oceania 8
Totale 11.238
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.083
FI - Finlandia 1.910
SG - Singapore 914
CN - Cina 463
IT - Italia 399
BR - Brasile 381
VN - Vietnam 284
HK - Hong Kong 230
DE - Germania 109
GB - Regno Unito 101
FR - Francia 91
BD - Bangladesh 83
CA - Canada 81
RU - Federazione Russa 62
TR - Turchia 61
JP - Giappone 59
UA - Ucraina 58
IN - India 57
PL - Polonia 56
SE - Svezia 55
AR - Argentina 41
MX - Messico 36
ID - Indonesia 29
ZA - Sudafrica 28
NL - Olanda 24
EC - Ecuador 22
IQ - Iraq 22
PH - Filippine 20
CO - Colombia 16
UZ - Uzbekistan 14
PK - Pakistan 13
ES - Italia 12
AT - Austria 11
JM - Giamaica 11
CR - Costa Rica 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
CZ - Repubblica Ceca 8
MY - Malesia 8
PR - Porto Rico 8
VE - Venezuela 8
BE - Belgio 7
HN - Honduras 7
LT - Lituania 7
AU - Australia 6
CW - ???statistics.table.value.countryCode.CW??? 6
KE - Kenya 6
PY - Paraguay 6
BO - Bolivia 5
CL - Cile 5
KR - Corea 5
UY - Uruguay 5
CH - Svizzera 4
DZ - Algeria 4
EG - Egitto 4
JO - Giordania 4
KZ - Kazakistan 4
MA - Marocco 4
PT - Portogallo 4
SA - Arabia Saudita 4
SV - El Salvador 4
TW - Taiwan 4
AZ - Azerbaigian 3
CI - Costa d'Avorio 3
GP - Guadalupe 3
IL - Israele 3
PE - Perù 3
RS - Serbia 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
BY - Bielorussia 2
ET - Etiopia 2
GA - Gabon 2
IE - Irlanda 2
KH - Cambogia 2
KW - Kuwait 2
LB - Libano 2
MN - Mongolia 2
NI - Nicaragua 2
NP - Nepal 2
PA - Panama 2
PS - Palestinian Territory 2
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
BG - Bulgaria 1
CV - Capo Verde 1
CY - Cipro 1
DK - Danimarca 1
EU - Europa 1
GE - Georgia 1
GF - Guiana Francese 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
Totale 11.065
Salva come PNG Salva come JPEG
Città #
Helsinki 1.886
Dallas 1.033
Ashburn 726
Singapore 509
San Jose 455
Santa Clara 251
Council Bluffs 247
Hong Kong 222
Beijing 195
Chandler 139
Fairfield 138
Los Angeles 118
Ferrara 109
Ho Chi Minh City 103
Houston 100
Ann Arbor 93
Woodbridge 85
New York 77
Hanoi 60
Tokyo 58
Jacksonville 56
Seattle 54
Warsaw 53
Wilmington 52
Princeton 47
Cambridge 46
Lauterbourg 46
Buffalo 40
São Paulo 37
Munich 33
Bologna 30
Chicago 28
Milan 27
Izmir 25
Orem 25
Phoenix 24
Shanghai 24
Toronto 23
Brooklyn 22
Chennai 21
Jakarta 21
London 21
Rome 19
San Diego 18
The Dalles 18
Washington 18
Atlanta 17
Mexico City 17
Montreal 17
Nuremberg 17
Da Nang 16
Johannesburg 15
North Bergen 14
Stockholm 14
Curitiba 13
Denver 13
Frankfurt am Main 13
Nanjing 13
Tashkent 13
Turku 13
Manchester 12
Baghdad 11
Boardman 11
Boston 11
Redondo Beach 11
San Francisco 11
Changsha 10
Poplar 10
Amsterdam 9
Falls Church 9
Quito 9
Brasília 8
Brno 8
Irvine 8
Rio de Janeiro 8
Buenos Aires 7
Calgary 7
Can Tho 7
Haiphong 7
Hefei 7
Hải Dương 7
Las Vegas 7
Salvador 7
Bari 6
Belo Horizonte 6
Brussels 6
Charlotte 6
Dhaka 6
Figino 6
Kingston 6
Lahore 6
Manila 6
San José 6
Venice 6
Willemstad 6
Biên Hòa 5
City of London 5
Guayaquil 5
Modena 5
Osasco 5
Totale 7.936
Salva come PNG Salva come JPEG
Nome #
[1,2,4]triazolo[1,5-c]pyrimidines as A(3) adenosine receptor antagonists 2.768
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 348
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation 298
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 288
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 242
Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer 237
7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A(1) and A(2A) adenosine receptors. Molecular modeling and pharmacological studies 218
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 207
Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists 207
The influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl moiety on the adenosine receptors affinity profile of pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c] pyrimidine derivatives 198
Design and synthesis of 1,4,8-triazaspiro[4.5]decan-2-one derivatives as novel mitochondrial permeability transition pore inhibitors 196
A 2a adenosine receptor: Structures, modeling, and medicinal chemistry 192
A3 adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states 178
A Multi-Angle Approach to Predict Peptide-GPCR Complexes: The N/OFQ-NOP System as a Successful AlphaFold Application Case Study 170
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 169
A QM/MM study of the binding of RAPTA ligands to cathepsin B 168
Probing non-peptide agonists binding at the human nociceptin/orphanin FQ receptor: a molecular modelling study 159
Bridging molecular docking to membrane molecular dynamics to investigate GPCR-ligand recognition: The human A2A adenosine receptor as a key study 150
Activation of carboplatin by carbonate: A theoretical investigation 130
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients 128
Aquaporin inhibition by gold(III) compounds: New insights 126
Activation of carboplatin by chloride ions: a theoretical investigation 125
DockBench: An Integrated Informatic Platform Bridging the Gap between the Robust Validation of Docking Protocols and Virtual Screening Simulations 125
Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists 122
Deciphering the Complexity of Ligand-Protein Recognition Pathways Using Supervised Molecular Dynamics (SuMD) Simulations 122
Sensitivity of Binding Free Energy Calculations to Initial Protein Crystal Structure 121
Understanding allosteric interactions in G protein-coupled receptors using Supervised Molecular Dynamics: A prototype study analysing the human A3 adenosine receptor positive allosteric modulator LUF6000 121
null 118
Conjugates between minor groove binders and Zn(II)-tach complexes: Synthesis, characterization, and interaction with plasmid DNA 117
New Trends in Inspecting GPCR-ligand Recognition Process: the Contribution of the Molecular Modeling Section (MMS) at the University of Padova 117
Probe Confined Dynamic Mapping for G Protein-Coupled Receptor Allosteric Site Prediction 116
Enhancing Ligand and Protein Sampling Using Sequential Monte Carlo 116
Advances in Computational Techniques to Study GPCR-Ligand Recognition 113
Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study 113
Structure-Guided Modification of Heterocyclic Antagonists of the P2Y 14 Receptor 112
Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-: E] [1,2,4]triazolo[1,5- c] pyrimidin-5-amine functionalized congeners 112
Supramolecular delivery systems for polyphenols: A green approach to predict in vivo permeability through an in vitro setup 111
Hidden GPCR structural transitions addressed by multiple walker supervised molecular dynamics (mwSuMD) 107
Pyrimidine nucleotides containing a (S)-methanocarba ring as P2Y6 receptor agonists 105
Design and in Vivo Characterization of A 1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series 100
Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT 99
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-Triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists 99
Repurposing of a nucleoside scaffold from adenosine receptor agonists to opioid receptor antagonists 97
Targeting Aquaporin Function: Potent Inhibition of Aquaglyceroporin-3 by a Gold-Based Compound 96
Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: Meeting new challenges 95
Demystifying P2Y1 Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses 94
Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists 92
Enhancing torsional sampling using fully adaptive simulated tempering 92
Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design 90
Journal of Medicinal Chemistry Collection: Drug Discovery in Italy 90
null 90
Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists 90
Synthesis and Spectroscopic Characterisation of a Heterodinuclear Iron(III)-Copper(II) Complex Based on an Asymmetric Dinucleating Ligand System 90
Implementing the “Best Template Searching” tool into Adenosiland platform 88
South (S)- and north (N)-methanocarba-7-deazaadenosine analogues as inhibitors of human adenosine kinase 88
Perturbation of fluid dynamics properties of water molecules during G protein-coupled receptor-ligand recognition: the human A2A adenosine receptor as a key study 86
Exploring the recognition pathway at the human A2A adenosine receptor of the endogenous agonist adenosine using supervised molecular dynamics simulations 83
Structural probing and molecular modeling of the A3 adenosine receptor: A focus on agonist binding 77
Influence of key amino acid mutation on the active site structure and on folding in acetyl-CoA synthase: A theoretical perspective 70
Polypharmacology of conformationally locked methanocarba nucleosides 67
In silico 3D modeling of binding activities 66
P2Y14 Receptor 63
HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS 62
Protein–Ligand Docking: Virtual Screening and Applications to Drug Discovery 60
The path to the G protein-coupled receptor structural landscape: Major milestones and future directions 58
Inspecting receptor-ligand interaction using molecular dynamics simulations: new insights from Adenosiland 58
The Effects of Variant Allele Frequency for EGFR Mutation on Early Tumor Shrinkage and Deepness of Response to Osimertinib in Patients with Metastatic Non-Small Cell Lung Cancer: An Exploratory Analysis 54
Not Quite Folded: Challenges in Predicting the hNPS‐hNPSR‐Ile107 Complex With AlphaFold2 Multimer 28
Design of New Potent, Selective, and Long-Acting NOP Receptor Agonists through Multiple Sequential d-Amino Acid Substitutions of [Arg14 Lys15]N/OFQ(1-15)-NH2 27
Fully Automatable Relative Binding Free Energy Calculations with Enhanced Sampling Using FAST/MBAR 18
The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na+ Binding and Preferentially Hinders the Protease Anticoagulant Functions 1
Totale 11.238
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.431
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.504
Totale 52.935
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022342 0 0 0 100 16 5 18 61 20 7 13 102
2022/2023313 51 22 24 21 40 26 8 44 47 9 13 8
2023/2024271 16 25 27 12 28 48 14 24 7 4 4 62
2024/20251.244 19 21 98 23 137 100 38 64 229 172 183 160
2025/20266.889 394 383 1.139 452 621 203 508 237 2.212 454 174 112
2026/20271.358 134 413 420 391 0 0 0 0 0 0 0 0
Totale 11.238